This Compendium Showcases a Selection of Useful and Reliable Online
JACKSONVILLE, Fla. and DEERFIELD, Ill., September 27, 2011 – The American Association of Clinical Endocrinologists (AACE) and Takeda Pharmaceuticals North America Inc. (Takeda) have partnered to launch the Diabetes Navigator (http://DiabetesNavigator.AACE.com), a compendium capturing a selection of useful and reliable type 2 diabetes information available online for patients and caregivers. This new compendium, reviewed and authored by leading clinical endocrinologists, was created to help health care professionals (HCPs) provide guidance for navigating through the abundance of online diabetes information.
“It is important for patients and caregivers to access educational resources they can trust; unfortunately, not all diabetes information online is useful or reliable,” said George Grunberger, M.D., AACE board member and founder and chairman at the Grunberger Diabetes Institute, Bloomfield Hills, Michigan. “The Diabetes Navigator assembles selected information that experts themselves use and refer to, which can serve as a basis for a well-informed disease management discussion among patients, caregivers and health care professionals.”
The Diabetes Navigator is a patient-friendly, easy-to-navigate website, divided into three categories: disease management, lifestyle, and tools. Using the compendium, visitors can identify and access reputable websites with key information about type 2 diabetes, working with a health care team and maintaining a healthy lifestyle. The Diabetes Navigator includes facts and figures, tips and trackers designed to help manage the disease, and provides guidance on how to search for reliable information online, including a list of reputable professional organizations and patient websites.
Content included in the Diabetes Navigator was authored and reviewed by Dr. Grunberger and the following endocrinologists:
“We are delighted to work with AACE to foster the exchange of knowledge and expertise within the type 2 diabetes community,” said Jennifer Greeby, director, diabetes marketing, Takeda Pharmaceuticals North America, Inc. “Diabetes is reaching epidemic proportions in the U.S. and worldwide. Takeda is committed to providing those affected by type 2 diabetes with expert information and insights to help manage type 2 diabetes.”
About Type 2 Diabetes
Type 2 diabetes is the most common form of diabetes in adults and has reached epidemic proportions globally. Almost 26 million Americans currently live with diabetes, and at least seven million are unaware that they have it. Type 2 diabetes is a progressive and chronic condition and patients should work with a health care professional to manage and monitor their disease. In addition to diet and exercise, patients often need to take multiple medications in order to help manage blood glucose control. The global health care expenditures to treat and prevent diabetes and its complications were estimated to reach $376 billion in 2010. By 2030, this number is projected to exceed $490 billion.
The American Association of Clinical Endocrinologists (AACE)
The American Association of Clinical Endocrinologists (AACE) represents more than 6,500 endocrinologists in the United States and abroad. AACE is the largest association of clinical endocrinologists in the world. The majority of AACE members are certified in Endocrinology and Metabolism and concentrate on the treatment of patients with endocrine and metabolic disorders including diabetes, thyroid disorders, osteoporosis, growth hormone deficiency, cholesterol disorders, hypertension and obesity. For more information about AACE, visit the AACE website at www.aace.com, become a fan on Facebook at www.facebook.com/theaace or follow AACE on Twitter at www.twitter.com/theaace.
Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc.
Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc. and Takeda Global Research & Development Center, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, and gastroenterology and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about these Takeda companies, visit www.tpna.com.
# # #
Elissa J. Johnsen
Takeda Pharmaceuticals North America, Inc.